

Organizational and Personnel Changes

TOKYO, January 30, 2020 -- <u>Chugai Pharmaceutical Co., Ltd.</u> (TOKYO: 4519) announced today the following organizational changes, effective April 1, 2020, and personnel changes, effective March 30 and April 1, 2020.

[Details of Organizational Changes] Effective April 1, 2020

- 1. Abolition of Secretarial Dept. and reorganization of secretarial function To enable efficient and flexible executive support, Secretarial Dept. will be integrated into General Affairs Dept., where Secretarial Office will be newly established. In addition, functions related to executive compensation will be transferred from Secretarial Dept. to Human Resources Management Dept. in order to integrate operation of the executive compensation system (directors and executive officers) and the personnel systems.
- 2. Abolition of PV & Safety Science Dept., and reorganization into two new departments (Drug Safety Div.)

To establish a safety strategy function capable of handling various new businesses, PV & Safety Science Dept. will be abolished and replaced by Safety Strategy Dept. and Pharmacovigilance Dept., which are newly established with the following aims.

- Safety Strategy Dept.: to strengthen the safety science function
- Pharmacovigilance Dept.: to improve efficiency and quality of the individual case safety report/the adverse drug reaction management
- 3. Renaming of Business Assessment Dept. (Project & Lifecycle Management Unit)
 Business Assessment Dept. will be renamed Business Insights & Strategy Dept. in order to describe the department's roles and mission more accurately and to ensure consistency with its counterpart at Roche while the Company will streamline and strengthen functions to capture business insights and create business strategies for in-house projects in early stages of development.

[Details of Personnel Changes]

Effective March 30, 2020

Directors

Name	New Responsibilities	Current Responsibilities
Tatsuro	Representative Director, Chairman	Representative Director, President
Kosaka	Chief Executive Officer (CEO)	CEO
	Supervisory responsibility for	Supervisory responsibility for External
	Corporate Planning, Business	Affairs, Pharmaceutical Technology,
	Development, External Affairs, and	and Marketing & Sales
	Foundation Medicine	
Osamu	Representative Director, President	Executive Vice President
Okuda	Chief Operating Officer (COO)	Supervisory responsibility for Project
	Supervisory responsibility for Project	& Lifecycle Management (Marketing),
	& Lifecycle Management, Regulatory	Foundation Medicine, Corporate
	& Quality Management, Clinical	Planning, and Business Development
	Development, Pharmaceutical	Co-Head of Project & Lifecycle
	Technology, Drug Safety, Medical	Management Unit
	Affairs, and Marketing & Sales	
	Co-Head of Project & Lifecycle	
	Management Unit	
Mariko	Director	
Momoi		

- Osamu Nagayama is scheduled to retire from Representative Director, Chairman as of March 30, 2020 and to be appointed as Honorary Chairman.
- Yasuo Ikeda is scheduled to retire from Director as of March 30, 2020.
- The appointment of Osamu Okuda and Mariko Momoi as Directors is subject to approval at the 109th Annual General Meeting of Shareholders, which is scheduled to be convened on March 30, 2020.

Executive officer

Name	New Responsibilities	Current Responsibilities
Yasushi	Executive Vice President	Executive Vice President
Ito	Co-Head of Project & Lifecycle	Supervisory responsibility for Project
	Management Unit	& Lifecycle Management (R&D),
		Regulatory & Quality Management,
		Clinical Development, Drug Safety,
		and Medical Affairs
		Co-Head of Project & Lifecycle
		Management Unit

Audit & Supervisory Board Member

Name	New Responsibilities	Current Responsibilities
Kenichi	Audit & Supervisory Board Member	
Masuda		

- The appointment of Kenichi Masuda as Audit & Supervisory Board Member is subject to approval at the 109th Annual General Meeting of Shareholders, which is scheduled to be convened on March 30, 2020.
- Hisashi Hara is scheduled to retire from Audit & Supervisory Board Member as of March 30, 2020.

Effective April 1, 2020

Director

Name	New Responsibilities	Current Responsibilities
Osamu	Representative Director, President	Representative Director, President
Okuda	coo	coo
	Supervisory responsibility for Project	Supervisory responsibility for Project
	& Lifecycle Management, Regulatory	& Lifecycle Management, Regulatory
	& Quality Management, Clinical	& Quality Management, Clinical
	Development, Pharmaceutical	Development, Pharmaceutical
	Technology, Drug Safety, Medical	Technology, Drug Safety, Medical
	Affairs, and Marketing & Sales	Affairs, and Marketing & Sales
		Co-Head of Project & Lifecycle
		Management Unit

Executive officers

Name	New Responsibilities	Current Responsibilities
Shinya	Deputy President	Executive Vice President
Unno	Supervisory responsibility for Human	Supervisory responsibility for Human
	Resources Management, Human	Resources Management, Human
	Capital Development, Legal,	Capital Development, Legal,
	Intellectual Property, and General	Intellectual Property, General Affairs,
	Affairs	and Secretarial
	In charge of General Affairs Dept.	General Manager of Human
		Resources Supervisory Div.
		In charge of General Affairs Dept. and
		Secretarial Dept.

Executive officers (Cont.)

Name	New Responsibilities	Current Responsibilities
Toshiaki	Executive Vice President	Executive Vice President
Itagaki	Chief Financial Officer (CFO)	CFO
	Supervisory responsibility for Finance	Supervisory responsibility for Finance
	& Accounting, Corporate	& Accounting, Corporate
	Communication, Purchasing, Digital	Communication, Purchasing, Digital
	Strategy, and IT Solution	Strategy, and IT Solution
	General Manager of Finance	General Manager of Finance
	Supervisory Div.	Supervisory Div. and General
		Manager of Finance & Accounting
		Dept.
Tetsuya	Senior Vice President	Vice President
Yamaguchi	General Manager of Corporate	General Manager of Business
	Planning Dept. and Head of	Development Dept.
	Foundation Medicine Unit	
Mark	Senior Vice President	
Noguchi	General Manager of Business	
	Development Dept.	
Minoru	Vice President	Vice President
Watanabe	Head of Project & Lifecycle	General Manager of Corporate
	Management Unit	Planning Dept. and Head of
		Foundation Medicine Unit
Shinji	Vice President	Vice President
Hidaka	General Manager of Marketing &	General Manager of Medical Affairs
	Sales Div.	Div.
Yoshiyuki	Vice President	Vice President
Yano	General Manager of Human	General Manager of Human
	Resources Supervisory Div. and	Resources Management Dept.
	General Manager of Human	
	Resources Management Dept.	
Junichi	Vice President	Associate Vice President
Nezu	General Manager of Research Div.	General Manager of Research Div.
Tsukasa	Vice President	Associate Vice President
Kusano	General Manager of Clinical	Deputy General Manager of
	Development Div.	Marketing & Sales Div.
Kaori	Vice President	Department Manager of Medical
Ouchi	General Manager of Medical Affairs	Science Dept., Medical Affairs Div.
	Div. and Department Manager of	
	Medical Science Dept., Medical	
	Affairs Div.	

Executive officers (Cont.)

Name	New Responsibilities	Current Responsibilities
Masatoshi	Vice President	Associate Vice President
Takada	Head of Kansai Regional	Head of Kansai Regional
	Management Office, Marketing &	Management Office, Marketing &
	Sales Div.	Sales Div.

- Yasushi Ito is scheduled to retire from Executive Vice President as of March 31, 2020.
- Toshihiko Komori, Hisanori Takanashi, Tsunanori Sato, and Kouichi Nishikawa are scheduled to retire from Vice Presidents as of March 31, 2020. Hisanori Takanashi is scheduled to be appointed as an Advisor (full-time).

Associate Vice Presidents

Name	New Responsibilities	Current Responsibilities
Shinya	Associate Vice President	Deputy General Manager of
Takuma	Deputy General Manager of	Pharmaceutical Technology Div. and
	Pharmaceutical Technology Div. and	President of Chugai Pharma
	President of Chugai Pharma	Manufacturing Co., Ltd.
	Manufacturing Co., Ltd.	
Takanori	Associate Vice President	Deputy General Manager of
Muto	Deputy General Manager of	Pharmaceutical Technology Div. and
	Pharmaceutical Technology Div. and	Department Manager of PT Planning
	Department Manager of PT Planning	Dept.
	Dept.	

⁻ Masahito Nagura is scheduled to retire from Associate Vice President as of March 31, 2020.

General Managers and Department Managers

Name	New Responsibilities	Current Responsibilities
Kazuya	General Manager of	Senior Specialist of
Usuda	Finance & Accounting Dept.	Finance & Accounting Dept.
Kae	General Manager of	Senior Specialist of
Miyata	Purchasing Dept.	Corporate Communications Dept.
Kouki	General Manager of	Senior Specialist of Audit Dept.
Harada	General Affairs Dept.	
Shinichi	Department Manager of	Department Manager of Clinical
Tsujimoto	Clinical Operation Dept.,	Information & Intelligence Dept.,
	Clinical Development Div.	Clinical Development Div.
Naoto	Department Manager of	Senior Specialist of Clinical
Awaji	Clinical Information & Intelligence	Information & Intelligence Dept.,
	Dept., Clinical Development Div.	Clinical Development Div.
Kenji	Department Manager of API Process	Senior Specialist of API Process
Maeda	Development Dept., Pharmaceutical	Development Dept., Pharmaceutical
	Technology Div.	Technology Div.

General Managers and Department Managers (Cont.)

Name	New Responsibilities	Current Responsibilities
Shin	Department Manager of Drug Safety	Department Manager of Risk
Yoshida	Coordination Dept., Drug Safety Div.	Communication Dept., Drug Safety
		Div.
Tatsuya	Department Manager of Risk	Senior Specialist of Risk
Kamiuchi	Communication Dept., Drug Safety	Communication Dept., Drug Safety
	Div.	Div.
Hidehiro	Department Manager of Safety	Specialist of Risk Communication
Tabata	Strategy Dept., Drug Safety Div.	Dept., Drug Safety Div.
Masahiko	Department Manager of	Senior Specialist of PV & Safety
Shibata	Pharmacovigilance Dept., Drug	Science Dept., Drug Safety Div.
	Safety Div.	
Takahito	Department Manager of Business	Department Manager of Business
Yamada	Insights & Strategy Dept., Project &	Assessment Dept., Project &
	Lifecycle Management Unit	Lifecycle Management Unit

Group Companies

Name	New Responsibilities	Current Responsibilities
Hirokazu	President of Chugai Clinical	Department Manager of Clinical
Furuta	Research Center Co., Ltd.	Operation Dept., Clinical
		Development Div.
Hidekazu	Plant Manager of Fujieda Plant,	Senior Specialist of Pharmaceutical
Haramoto	Chugai Pharma Manufacturing Co.,	Technology Div.
	Ltd.	
Kenji	Department Manager of Quality	Senior Specialist of R&D Portfolio
Kamada	Development Dept., Chugai Pharma	Management Dept., Project &
	Manufacturing Co., Ltd.	Lifecycle Management Unit

###